Non-interventional Study Describing Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms SPAF
- Sponsors Boehringer Ingelheim
- 03 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Jul 2018 Planned End Date changed from 19 Jul 2018 to 31 Aug 2018.
- 31 Jul 2018 Planned primary completion date changed from 19 Jul 2018 to 31 Aug 2018.